UPDATE 1-Bristol to take $1.8 bln charge on hep C drug failure

Aug 24 (Reuters) - Bristol-Myers Squibb Co said it
would record a $1.8 billion charge related to the
discontinuation of its much-anticipated hepatitis C drug that
was dropped after a patient died of heart failure.

tools for home inspectors easy web building software home mold testing kits